WO2000001719A3 - Peptides du virus varicelle-zona et autres virus permettant d'assurer un diagnostic et une therapie dans le cas du vih-2 - Google Patents
Peptides du virus varicelle-zona et autres virus permettant d'assurer un diagnostic et une therapie dans le cas du vih-2 Download PDFInfo
- Publication number
- WO2000001719A3 WO2000001719A3 PCT/US1999/015114 US9915114W WO0001719A3 WO 2000001719 A3 WO2000001719 A3 WO 2000001719A3 US 9915114 W US9915114 W US 9915114W WO 0001719 A3 WO0001719 A3 WO 0001719A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hiv
- peptides
- loop
- varicella
- therapy
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 6
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 5
- 238000002560 therapeutic procedure Methods 0.000 title abstract 2
- 208000007514 Herpes zoster Diseases 0.000 title 1
- 241000700605 Viruses Species 0.000 title 1
- 238000003745 diagnosis Methods 0.000 title 1
- 241000725303 Human immunodeficiency virus Species 0.000 abstract 3
- 108091006116 chimeric peptides Proteins 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 230000003612 virological effect Effects 0.000 abstract 2
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 abstract 1
- 208000031886 HIV Infections Diseases 0.000 abstract 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 abstract 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 abstract 1
- 241000713340 Human immunodeficiency virus 2 Species 0.000 abstract 1
- 101800001690 Transmembrane protein gp41 Proteins 0.000 abstract 1
- 125000000539 amino acid group Chemical group 0.000 abstract 1
- 230000036436 anti-hiv Effects 0.000 abstract 1
- 230000000890 antigenic effect Effects 0.000 abstract 1
- 229960003067 cystine Drugs 0.000 abstract 1
- 238000002405 diagnostic procedure Methods 0.000 abstract 1
- 230000002209 hydrophobic effect Effects 0.000 abstract 1
- 230000009257 reactivity Effects 0.000 abstract 1
- 241000894007 species Species 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
Abstract
L'invention concerne des peptides chimères utiles à des fins de diagnostic et de thérapie pour le VIH. Ils comprennent une séquence en boucle issue de la protéine du virus varicelle-zona et une ou plusieurs parties additionnelles qui améliorent la réactivité antigénique de la boucle vis-à-vis d'un anticorps anti-VIH. Généralement, les peptides ont une longueur d'au moins 16 acides aminés et, ce qui est avantageux, ils renferment des parties additionnelles qui ont une identité de séquence avec les séquences peptidiques qui sont adjacentes à une boucle de cystine de gp41 du VIH-1. Les peptides en question ont une activité immunologique croisée avec la protéine d'un large éventail de souches du VIH-2. Selon certaines variantes, les peptides considérés sont moins hydrophobes et plus basiques, ce qui permet d'améliorer leur solubilité dans l'eau par rapport aux peptides issus de souches de VIH d'origine naturelle. Lesdits peptides chimères diffèrent largement des séquences d'origine naturelle et ne sont pas identifiés comme correspondant à des espèces ou à des souches virales particulières.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU48577/99A AU4857799A (en) | 1998-07-02 | 1999-07-02 | Peptides from (varicella-zoster) and other viruses for hiv-2 diagnosis and therapy |
| EP99932223A EP1091976A2 (fr) | 1998-07-02 | 1999-07-02 | Peptides du virus varicelle-zona et autres virus permettant d'assurer un diagnostic et une therapie dans le cas du vih-2 |
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9165998P | 1998-07-02 | 1998-07-02 | |
| US60/091,659 | 1998-07-02 | ||
| US10468598P | 1998-10-16 | 1998-10-16 | |
| US60/104,685 | 1998-10-16 | ||
| US11202698P | 1998-12-11 | 1998-12-11 | |
| US60/112,026 | 1998-12-11 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2000001719A2 WO2000001719A2 (fr) | 2000-01-13 |
| WO2000001719A3 true WO2000001719A3 (fr) | 2000-02-24 |
Family
ID=27376950
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US1999/015114 WO2000001719A2 (fr) | 1998-07-02 | 1999-07-02 | Peptides du virus varicelle-zona et autres virus permettant d'assurer un diagnostic et une therapie dans le cas du vih-2 |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP1091976A2 (fr) |
| AU (1) | AU4857799A (fr) |
| WO (1) | WO2000001719A2 (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2817604B1 (fr) | 2000-12-01 | 2004-04-23 | Biomerieux Sa | Vannes activees par des polymeres electro-actifs ou par des materiaux a memoire de forme, dispositif contenant de telles vannes et procede de mise en oeuvre |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995023973A2 (fr) * | 1994-03-02 | 1995-09-08 | Abbott Laboratories | Dosage immunologique vih a l'aide de proteines recombinantes et de reactifs peptidiques de synthese |
| WO1995033206A1 (fr) * | 1994-05-31 | 1995-12-07 | Abbott Laboratories | Detection de differents genotypes de vih utilisant un immunodosage modifie par un peptide synthetique |
| WO1999045395A1 (fr) * | 1998-03-04 | 1999-09-10 | Universal Healthwatch, Inc. | Test de confirmation rapide d'infections microbiennes |
-
1999
- 1999-07-02 EP EP99932223A patent/EP1091976A2/fr not_active Withdrawn
- 1999-07-02 WO PCT/US1999/015114 patent/WO2000001719A2/fr not_active Application Discontinuation
- 1999-07-02 AU AU48577/99A patent/AU4857799A/en not_active Abandoned
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995023973A2 (fr) * | 1994-03-02 | 1995-09-08 | Abbott Laboratories | Dosage immunologique vih a l'aide de proteines recombinantes et de reactifs peptidiques de synthese |
| WO1995033206A1 (fr) * | 1994-05-31 | 1995-12-07 | Abbott Laboratories | Detection de differents genotypes de vih utilisant un immunodosage modifie par un peptide synthetique |
| WO1999045395A1 (fr) * | 1998-03-04 | 1999-09-10 | Universal Healthwatch, Inc. | Test de confirmation rapide d'infections microbiennes |
Non-Patent Citations (4)
| Title |
|---|
| AIDS RES. HUM. RETROVIRUSES (1989), 5(5), 487-93, 1989 * |
| CHEMICAL ABSTRACTS, vol. 112, no. 11, 12 March 1990, Columbus, Ohio, US; abstract no. 96724, NORRBY, ERLING ET AL: "The chemistry of site-directed serology for HIV infections" XP002126794 * |
| CHEMICAL ABSTRACTS, vol. 122, no. 23, 5 June 1995, Columbus, Ohio, US; abstract no. 288341, TANCHOU, V. ET AL: "B-cell continuous epitopes of the SIVmac-251 envelope protein in experimentally infected macaques" XP002126793 * |
| RES. VIROL. (1995), 146(1), 19-32, 1995 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1091976A2 (fr) | 2001-04-18 |
| WO2000001719A2 (fr) | 2000-01-13 |
| AU4857799A (en) | 2000-01-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE154610T1 (de) | Synthetische vom hiv-gp120-env-protein abgeleitete peptide und ihre anwendung | |
| DK1278534T3 (da) | Fremgangsmåder og sammensætninger til svækkelse af multiplikationen af HIV-1 | |
| KR950032278A (ko) | 사람 면역결핍 바이러스 그룹의 레트로바이러스로부터 유래된 펩타이드 및 이의 용도 | |
| DK33190A (da) | Hiv-3 retrovirus og anvendelse heraf | |
| DK513388D0 (da) | Peptider med immunologiske egenskaber svarende til hiv-2 virus, nucleotidsekvenser, der koder for saadanne peptider, antigene og immunogene midler indeholdende saadanne peptider samt fremgangsmaade og kit til in vitro diagnose af hiv-2 | |
| DE69128108D1 (de) | Monoklonaler Antikörper gegen HTLV-III (Stamm MN) | |
| EP0246829A3 (en) | Htlv-iii virus related peptides, antibodies to the peptides, vaccines, passive and active immunization against aids virus and diagnostic test for the serological detection of the aids virus | |
| WO2000001719A3 (fr) | Peptides du virus varicelle-zona et autres virus permettant d'assurer un diagnostic et une therapie dans le cas du vih-2 | |
| Matthews et al. | Prospects for development of a vaccine against HTLV-III-related disorders | |
| WO2003022879B1 (fr) | Peptides imitant un epitope cryptique de gp41 de hiv-1 | |
| GB2336844A (en) | Anti-hiv peptides and proteins | |
| ZA907944B (en) | Hiv related peptides | |
| CA2057612A1 (fr) | Peptides selectionnes de l'antigene specifique au groupe (gag) du virus de l'immunodeficience humaine (vih), sa preparation et son utilisation | |
| Mohlbacher et al. | Longitudinal Study of Antibody Reactivity against HIV-1 Envelope and a Peptide Representing a Conserved Site on Gp4l in HIV-1-Infected Patients | |
| WO2001029177A3 (fr) | Peptides de sous-type d du hiv-1 | |
| DK0462551T3 (da) | Monoklonale antistoffer mod HIV gp120 | |
| WO1999062945A3 (fr) | Peptides universels | |
| RU96116005A (ru) | Штамм hominis immunodeficiti virus (hiv-i) вич-i/россия/гм-12-95 (ru1295) субтипа в для диагностических и вакцинных препаратов | |
| HK1028065A1 (en) | Peptides for the detection of hiv-1-group o. | |
| EP0293792A3 (fr) | Protéines encodées par GAG du virus d'immunodéficience humaine | |
| Ivanoff et al. | Human immunodeficiency virus antigen. | |
| RU2007108306A (ru) | Модифицированные пептиды вич-1 и их применение для обнаружения антител против вич | |
| RU2000106709A (ru) | Пептиды-имитаторы консервативного эпитопа белка gp41 вируса иммунодефицита человека типа 1, узнаваемого вируснейтрализующими моноклональными антителами 2f5 | |
| WO1991009872A3 (fr) | Polypeptides selectivement reactifs avec des anticorps contre le virus d'immunodeficience humaine et vaccins comprenant les polypeptides |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US US US UZ VN YU ZA ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
| AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US US US UZ VN YU ZA ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 1999932223 Country of ref document: EP |
|
| WWP | Wipo information: published in national office |
Ref document number: 1999932223 Country of ref document: EP |
|
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
| WWW | Wipo information: withdrawn in national office |
Ref document number: 1999932223 Country of ref document: EP |